AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations
Status:
Active, not recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This study will test the recommended dose of AZD5363 (recommended from a previous phase 1
study of the drug) in patients with specific AKT mutations. In patients who have ER positive
breast cancer with an AKT mutation, they will also be receiving a standard breast cancer drug
called fulvestrant that is given as an injection. In patients who have prostate cancer with
an AKT mutation, they will also be receiving a standard prostate cancer drug called
enzalutamide that is taken orally.